109 completed, 5 recruiting, 3 unknown, 2 active not recruiting. 119 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 119 | Completed 109, Recruiting 5, Unknown 3, Active not recruiting 2 |
| Phase 2 | 6 | Completed 4, Recruiting 1, Unknown 1 |
Follow Meningococcal Infections: new trials by email Literature Review of Meningococcal Infections trials Research Report on Meningococcal Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in China MenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Toxoid Conjugate Vaccine) (Sanofi Pasteur Inc., Swiftwater, PA, USA), Menhycia® (ACYW135 Meningococcal Conjugate Vaccine [CRM197]) (CanSino Biologics Inc., China) - Meningococcal Infection, Healthy Volunteers | Phase 3 | Recruiting | Sanofi | 4568 | 2026-08-22 | 2026-10-19 |
| Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 3-5 Months experimental vaccine, Active Comparator vaccine - Epidemic Meningitis, Meningococcal Vaccines | Phase 3 | Recruiting | Sinovac Biotech Co., Ltd | 880 | 2026-03-25 | 2026-08-10 |
| Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 Months experimental vaccine, Active Comparator vaccine - Epidemic Meningitis, Meningococcal Vaccines | Phase 3 | Recruiting | Sinovac Biotech Co., Ltd | 1040 | 2026-03-22 | 2026-08-10 |
| Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 6-11 Months experimental vaccine, Active Comparator vaccine - Epidemic Meningitis, Meningococcal Vaccines | Phase 3 | Recruiting | Sinovac Biotech Co., Ltd | 1040 | 2026-03-22 | 2026-08-10 |
| Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years experimental vaccine, active comparator vaccine - Epidemic Meningitis, Meningococcal Vaccines | Phase 3 | Active not recruiting | Sinovac Biotech Co., Ltd | 660 | 2026-03-22 | 2026-08-10 |
| Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old EG-MCV4, Menveo - Meningococcal Infections | Phase 2 / Phase 3 | Recruiting | EyeGene Inc. | 1123 | 2025-10-15 | 2025-12-01 |
| Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China MenACYW conjugate vaccine, MenACYW135 polysaccharide vaccine, MenAC conjugate vaccine - Meningococcal Infection, Healthy Volunteers | Phase 3 | Completed | Sanofi | 1602 | 2025-09-26 | 2026-10-19 |
| A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds MCV4, MPSV4 - Meningococcal Meningitis | Phase 3 | Completed | CanSino Biologics Inc. | 840 | 2024-12-14 | 2026-08-06 |
| A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4), batch 2 of MCV4, batch 3 of MCV4 - Meningococcal Meningitis | Phase 3 | Completed | CanSino Biologics Inc. | 1480 | 2024-03-20 | 2026-08-06 |
| A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds MCV4, MPSV4 - Meningococcal Meningitis | Phase 3 | Active not recruiting | CanSino Biologics Inc. | 840 | 2024-03-01 | 2025-07-29 |
| Study on a MenACYW Conjugate Vaccine Administered as a Single Dose in Participants Aged 12 Months and Older in Vietnam Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine - Meningococcal Infection, Healthy Volunteers | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 447 | 2024-01-18 | 2025-09-17 |
| A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population MCV4, MSPV4 - Epidemic Meningitis | Phase 3 | Completed | CanSino Biologics Inc. | 1000 | 2023-09-16 | 2025-07-03 |
| Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months Meningococcal ACYW135 Polysaccharide Conjugate Vaccine, Meningococcal A and C Polysaccharide Conjugate Vaccine - Meningitis, Meningococcal | Phase 3 | Unknown | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 1200 | 2021-12-18 | 2024-04-04 |
| Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine MenABCWY vaccine, Placebo, MenACWY vaccine - Meningitis, Meningococcal | Phase 3 | Completed | GlaxoSmithKline | 1250 | 2021-01-25 | 2024-07-03 |
| A Phase III Clinical Trial of the Group A and C Meningococcal Polysaccharide Vaccine Experimental Group A and C meningococcal polysaccharide vaccine, Control Group A and C meningococcal polysaccharide vaccine - Meningitis, Meningococcal | Phase 3 | Completed | Institute of Medical Biology, Chinese Academy of Medical Sciences | 1280 | 2020-09-15 | 2026-09-29 |
| A Phase III Clinical Trial of the Group A Meningococcal Polysaccharide Vaccine Experimental Group A meningococcal polysaccharide vaccine, Control Group A meningococcal polysaccharide vaccine - Meningitis, Meningococcal | Phase 3 | Unknown | Wei Cun | 1280 | 2020-09-14 | 2020-12-30 |
| Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ), Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid), Placebo - Infections, Meningococcal | Phase 3 | Completed | GlaxoSmithKline | 945 | 2020-08-25 | 2025-03-04 |
| Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults rMenB+OMV NZ vaccine, Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY), Placebo - Infections, Meningococcal | Phase 3 | Completed | GlaxoSmithKline | 3657 | 2020-08-14 | 2024-03-05 |
| Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49 Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Blood sample - Meningococcal Infection (Healthy Volunteers) | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 471 | 2019-10-04 | 2025-09-11 |
| Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5) NmCV-5, Menactra - Meningococcal Meningitis | Phase 3 | Completed | Serum Institute of India Pvt. Ltd. | 1800 | 2019-08-20 | 2021-07-27 |
Showing 20 of 119. Sign in to see all of them.
Meningitis, Meningococcal (54) · Meningitis (39) · Haemophilus Infections (6) · Tetanus (6) · Whooping Cough (5) · Chickenpox (4) · Hepatitis B (4) · Measles (4) · Mumps (4) · Rubella (4) · Diphtheria (3) · Central Nervous System Diseases (2) · Fever (2) · Nervous System Diseases (2)
Bacterial Infections and Mycoses (119) · Neisseriaceae Infections (119) · Bacterial Infections (118) · Gram-Negative Bacterial Infections (118) · Infections (118) · Neuroinflammatory Diseases (74) · Nervous System Diseases (72) · Central Nervous System Diseases (56) · Central Nervous System Infections (56) · Central Nervous System Bacterial Infections (55) · Meningitis, Bacterial (54) · Meningitis (34) · Virus Diseases (11) · DNA Virus Infections (9)
Meningococcal Vaccines (27) · MenACWY-CRM vaccine (10) · 4CMenB vaccine (9) · 13-valent pneumococcal vaccine (8) · Hepatitis B Vaccines (8) · Measles-Mumps-Rubella Vaccine (8) · Tetanus Toxoid (8) · Heptavalent Pneumococcal Conjugate Vaccine (6) · diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (6) · Chickenpox Vaccine (5) · measles, mumps, rubella, varicella vaccine (5) · Blood Specimen Collection (4) · Hepatitis A Vaccines (4) · PEDIARIX (4) · Rotavirus Vaccines (4)
GlaxoSmithKline (34) · Novartis Vaccines (29) · Sanofi Pasteur, a Sanofi Company (25) · Pfizer (7) · Novartis (5) · CanSino Biologics Inc. (4) · Sinovac Biotech Co., Ltd (4) · Sanofi (3) · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (1) · EyeGene Inc. (1) · Institute of Medical Biology, Chinese Academy of Medical Sciences (1) · Merck Sharp & Dohme LLC (1) · Public Health England (1) · Serum Institute of India Pvt. Ltd. (1) · The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) (1)
United States (31) · Germany (18) · China (13) · Czechia (13) · Finland (13) · Puerto Rico (10) · Spain (10) · Australia (9) · Canada (9) · Italy (9) · Philippines (7) · Mexico (6) · South Korea (6) · Argentina (5) · Chile (5)
Elizabeth Miller, MD (1) · Isti Suharjanti, Dr (1) · Lin Du (1)
PMID 23324563, PMID 29253560, PMID 31110098, PMID 33020485, PMID 33325757, PMID 19476428, PMID 19812260, PMID 19895922, PMID 20164251, PMID 20189491, PMID 20655261, PMID 20943209, PMID 21339701, PMID 21343698, PMID 21389149, PMID 22094635, PMID 22260988, PMID 22327493, PMID 22855388, PMID 24873986, PMID 25152325, PMID 25285126, PMID 25305567, PMID 25308927, PMID 25483566, PMID 26075813, PMID 26232542, PMID 26398741, PMID 26479973, PMID 26756390, PMID 26826544, PMID 28318767, PMID 28580917, PMID 29038320, PMID 29784470, PMID 29789243, PMID 29960800, PMID 30068713, PMID 30691980, PMID 30770221, PMID 31116180, PMID 31279564, PMID 31327652, PMID 32209015, PMID 32284274, PMID 32387012, PMID 32552685, PMID 32598244, PMID 32852352, PMID 33814028
2016 (5), 2017 (4), 2019 (4), 2009 (3), 2008 (2), 2014 (2), 2018 (2), 2005 (1)